Prof. Frank Leebeek: About 20 % of People with Von Willebrand’s Disease Have Something Strange Going On
Erasmus MC shared a post on LinkedIn:
“Scientists at Erasmus MC have discovered that Von Willebrand’s blood clotting disease is not always caused by an error in the gene of the same name. A problem in the secretion of the clotting protein can also trigger the disease, they showed.
In people with Von Willebrand disease, something goes wrong in blood clotting. This is usually because their body produces too little or a poorly functioning version of the clotting protein Von Willebrand factor. That protein acts as a kind of band-aid to stop bleeding.
About twenty percent of people with Von Willebrand’s disease have something strange going on. They do not have an error in the Von Willebrand factor gene, but they do have too little clotting protein in their blood. “We have been looking for years to find out what causes the disease in these people,” says hematologist Prof. Frank Leebeek of Erasmus MC. A recent study by the Department of Hematology, published in Blood, points to a new cause.”
Read full paper here.
Stay updated with Hemostasis Today.
-
Dec 15, 2025, 15:58Khaled Musallam Applauds Hatoon Ezzat’s Leadership and Healthcare Advances in Saudi Arabia
-
Dec 15, 2025, 12:46Deborah Ebert Long on Hemophilia Care: Progress, Possibility, and the Power of Listening
-
Dec 15, 2025, 12:34Nathan Connell on Conversion from Eptacog Alfa to Beta
-
Dec 15, 2025, 12:17Danny Hsu on Interdisciplinary Toolkit for Gynecologic Bleeding on Anticoagulation
-
Dec 15, 2025, 12:08Ted Roh: A Historic Milestone for Indonesia’s Health Innovation
-
Dec 15, 2025, 11:28Wolfgang Miesbach Shares Insights from Davide Matino’s Presentation on Marstacimab at ASH25
-
Dec 15, 2025, 11:12Tushar Pandey Awarded for His Enourmous Contribution to Hematology
-
Dec 15, 2025, 11:07DISTRO: Vidya Rajbhoj on AI and Digital Technology to Improve Stroke Rehabilitation
-
Dec 15, 2025, 11:00Ischemic Stroke, AF and Atherosclerotis: Amira Khater on Sufficiency of Anticoagulant Monotherapy